# EXEL catalysts: EXELIXIS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/exel/catalysts

> EXELIXIS, INC. (EXEL) has 17 upcoming catalysts. The next is the XL092 topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | EXELIXIS, INC. |
| Ticker | EXEL (Nasdaq) |
| SEC CIK | 939767 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/exel |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 25, 2016 | [Cabometyx (cabozantinib s-malate) FDA approval](https://sec-api.dev/pdufa/cabozantinib-s-malate) | EXEL |  | completed, approved | "NDA208692 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160425, review_priority PRIORITY; sponsor_name EXELIXIS INC; product CABOMETYX (CABOZANTINIB S-MALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208692%22)) |
| January 22, 2021 | [Cabometyx (cabozantinib s-malate) label expansion decision](https://sec-api.dev/pdufa/cabozantinib-s-malate) | EXEL |  | completed, approved | "NDA208692 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20210122, review_priority PRIORITY; sponsor_name EXELIXIS INC; product CABOMETYX (CABOZANTINIB S-MALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208692%22)) |
| September 17, 2021 | [Cabometyx (cabozantinib s-malate) label expansion decision](https://sec-api.dev/pdufa/cabozantinib-s-malate) | EXEL |  | completed, approved | "NDA208692 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20210917, review_priority PRIORITY; sponsor_name EXELIXIS INC; product CABOMETYX (CABOZANTINIB S-MALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208692%22)) |
| July 14, 2022 | [Cabometyx (cabozantinib s-malate) label expansion decision](https://sec-api.dev/pdufa/cabozantinib-s-malate) | EXEL |  | completed, approved | "NDA208692 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20220714, review_priority STANDARD; sponsor_name EXELIXIS INC; product CABOMETYX (CABOZANTINIB S-MALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208692%22)) |
| Aug 2023 | [CABOMETYX® (cabozantinib) topline data readout](https://sec-api.dev/pdufa/cabozantinib) | EXEL | measurable, extra-pelvic metastatic castration-resistant prostate cancer | completed, positive | "In August 2023, we announced positive top-line results from CONTACT-02, a phase 3 pivotal trial sponsored by us and co-funded by Roche, evaluating the combination of cabozantinib and Roche's ICI, atezolizumab, versus a second novel hormonal therapy (NHT) in patients with measurable, extra-pelvic metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with one prior NHT." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/939767/000093976725000113/exel-20250704.htm)) |
| Aug 2024 | [CABOMETYX® (cabozantinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/cabozantinib) | EXEL |  | completed | "In August 2024, we announced that the FDA had accepted our sNDA seeking approval for cabozantinib to" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm)) |
| 1H 2025 | [Zanzalintinib trial start](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | advanced NET, regardless of site of origin | scheduled | "•Exelixis also expects to initiate STELLAR-311, a phase 3 pivotal trial evaluating zanzalintinib compared with everolimus as a first oral therapy in patients with advanced NET, regardless of site of origin, in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000004/exel20250112exhibit991.htm)) |
| 1H 2025 | [Zanzalintinib interim data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | scheduled | "We anticipate initial clinical data readouts from STELLAR-002 in the first half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/939767/000093976725000075/exel-20250404.htm)) |
| January 12, 2025 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000004/exel20250112exhibit991.htm)) |
| February 11, 2025 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel2024q42024exhibit991.htm)) |
| Mar 2025 | [CABOMETYX® (cabozantinib) FDA advisory committee meeting](https://sec-api.dev/pdufa/cabozantinib) | EXEL |  | scheduled | "In November 2024, we announced that our sNDA would be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025; however, in January 2025, we announced that the FDA had notified us that our sNDA would no longer be the subject of discussion at an ODAC." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm)) |
| Mar 2025 | [CABOMETYX® (cabozantinib) FDA approval](https://sec-api.dev/pdufa/cabozantinib) | EXEL | previously treated advanced NET | completed, approved | "In March 2025, the U.S. FDA approved CABOMETYX for two new NET indications, advanced pancreatic and extra-pancreatic NET (pNET and epNET), based on results from the CABINET study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm)) |
| March 26, 2025 | [Cabometyx (cabozantinib s-malate) label expansion decision](https://sec-api.dev/pdufa/cabozantinib-s-malate) | EXEL |  | completed, approved | "NDA208692 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20250326, review_priority STANDARD; sponsor_name EXELIXIS INC; product CABOMETYX (CABOZANTINIB S-MALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208692%22)) |
| Apr 2025 | [XB628 trial start](https://sec-api.dev/pdufa/xb628) | EXEL |  | completed | "In April 2025, we initiated the phase 1 study of XB628, a first-in-class bispecific antibody that simultaneously targets PD-L1 and NKG2A, identified as key regulators of adaptive and innate immune cell activity, discovered, in part, in collaboration with Invenra." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)) |
| April 3, 2025 | [CABOMETYX® (cabozantinib) PDUFA date](https://sec-api.dev/pdufa/cabozantinib) | EXEL | with previously treated advanced NET | completed, approved | "In January 2025, Exelixis announced its key priorities and anticipated milestones for 2025, including: the potential commercial launch of CABOMETYX for the treatment of patients with previously treated advanced NET following completion of the FDA's review of Exelixis' sNDA, which has a PDUFA action date of April 3, 2025; expansion of zanzalintinib's pivotal development program with six ongoing or planned pivotal trials, including two pivotal RCC studies with Merck and additional" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel2024q42024exhibit991.htm)) |
| May 13, 2025 | [CABOMETYX® (cabozantinib) FDA approval](https://sec-api.dev/pdufa/cabozantinib) | EXEL |  | completed, approved | "In March, Exelixis announced that the U.S. FDA approved CABOMETYX for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET); and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/exel20250331exhibit991.htm)) |
| May 13, 2025 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/exel20250331exhibit991.htm)) |
| Jun 2025 | [Stivarga® (regorafenib) topline data readout](https://sec-api.dev/pdufa/regorafenib) | EXEL |  | completed, met | "In June 2025, we announced positive top-line results in the first dual primary endpoint, demonstrating a statistically significant improvement in OS versus regorafenib in the intention-to-treat (ITT) population, and in October 2025, announced that the study demonstrated a 20% reduction in the risk of death versus regorafenib in the ITT population at the final analysis (stratified hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.69-0.93; P=0.0045)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/939767/000093976726000116/exel-20261002.htm)) |
| Jun 2025 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | completed, positive | "•In June 2025, we announced positive top-line results from the STELLAR-303 phase 3 pivotal trial that the study met one of its dual primary endpoints, OS in the ITT population, with the OS benefit of the zanzalintinib and atezolizumab combination consistently observed across pre-specified subgroups." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)) |
| July 28, 2025 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel20250630exhibit991.htm)) |
| July 28, 2025 | [Zanzalintinib trial start](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | completed | "We also initiated the STELLAR-311 pivotal study in advanced NET during the quarter and plan to announce an additional wave of zanzalintinib pivotal trials in the coming months." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel20250630exhibit991.htm)) |
| Aug 2025 | [XB371 trial start](https://sec-api.dev/pdufa/xb371) | EXEL |  | completed | "In August 2025, we initiated a phase 1 study of XB371, a next-generation TF-targeting ADC with a topoisomerase inhibitor payload, which was discovered, in part, in collaboration with Catalent." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)) |
| late 2025 | [Zanzalintinib NDA/BLA submission](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | with previously treated metastatic CRC | scheduled | "Based on these findings, Exelixis intends to submit a New Drug Application for zanzalintinib in combination with atezolizumab for the treatment of patients with previously treated metastatic CRC in the U.S. by the end of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/exel20250930exhibit991.htm)) |
| September 10, 2025 | [Cabometyx (cabozantinib s-malate) label expansion decision](https://sec-api.dev/pdufa/cabozantinib-s-malate) | EXEL |  | completed, approved | "NDA208692 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20250910, review_priority STANDARD; sponsor_name EXELIXIS INC; product CABOMETYX (CABOZANTINIB S-MALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208692%22)) |
| November 4, 2025 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/exel20250930exhibit991.htm)) |
| Dec 2025 | [Zanzalintinib NDA/BLA submission](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | completed | "We submitted our first NDA to the FDA for zanzalintinib in December 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm)) |
| 1H 2026 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | scheduled | "In May, we completed enrollment into the STELLAR-304 pivotal study in non-clear cell renal cell carcinoma with top-line results expected in the first half of 2026, depending on study event rates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel20250630exhibit991.htm)) |
| January 11, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000003/exel20260111exhibit991.htm)) |
| February 10, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm)) |
| February 10, 2026 | [Zanzalintinib NDA/BLA acceptance](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | previously treated metastatic CRC, when used in combination with atezolizumab | completed | "In February 2026, Exelixis announced that the FDA accepted its NDA for zanzalintinib as a treatment for patients with previously treated metastatic CRC, when used in combination with atezolizumab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm)) |
| mid-2026 | [EXELIXIS, INC. topline data readout](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | scheduled | "Top-line results are expected in the first half of 2026, depending on study event rates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel20250630exhibit991.htm)) |
| mid-2026 | [Zanzalintinib trial start](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | scheduled | "Exelixis remains on track to initiate the planned phase 3 STELLAR-316 pivotal trial of zanzalintinib in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm)) |
| May 5, 2026 | [Zanzalintinib trial start](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | recurrent Grade I/II/III meningioma with relapse or progression | completed | "Today, Exelixis announced it has initiated STELLAR-201, a phase 2 trial evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for these therapies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm)) |
| May 5, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm)) |
| June 16, 2026 | [XL092 primary completion](https://sec-api.dev/pdufa/xl092) | EXEL | Colorectal Cancer | completed | "NCT05425940 (Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-16 (ACTUAL); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05425940)) |
| 2H 2026 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | scheduled | "Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in Second Half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm)) |
| Aug 2026 | [Zanzalintinib trial start](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | resected stage II/III CRC | completed | "In August 2026, Exelixis initiated the phase 3 STELLAR-316 pivotal trial evaluating zanzalintinib, with and without KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), in patients with resected stage II/III CRC who," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm)) |
| August 5, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm)) |
| October 29, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm)) |
| Dec 2026 to Mar 2027 | [XL092 topline data readout](https://sec-api.dev/pdufa/xl092) | EXEL | Non-Clear Cell Renal Cell Carcinoma | scheduled | "NCT05678673 (Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05678673)) |
| December 3, 2026 | [Zanzalintinib PDUFA date](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | previously treated metastatic colorectal cancer | scheduled | ""Our first New Drug Application for zanzalintinib, for its initial potential indication in previously treated metastatic colorectal cancer, was accepted by U.S. regulatory authorities and is under active review, with a target action date of December 3, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm)) |
| December 2026 | [XL092 primary completion](https://sec-api.dev/pdufa/xl092) | EXEL | Non-Clear Cell Renal Cell Carcinoma | scheduled | "NCT05678673 (Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05678673)) |
| Q1 2027 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | scheduled | "Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in First Quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm)) |
| March 3, 2027 | [Zanzalintinib PDUFA date](https://sec-api.dev/pdufa/zanzalintinib) | EXEL |  | scheduled | "Ongoing Regulatory Review of Zanzalintinib in Combination with Atezolizumab (Tecentriq®) for Previously Treated Metastatic CRC with Prescription Drug User Fee Act (PDUFA) Target Action Date of March 3, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm)) |
| Feb to May 2028 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Meningioma | scheduled | "NCT07428616 (A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07428616)) |
| February 2028 | [Zanzalintinib primary completion](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Meningioma | scheduled | "NCT07428616 (A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07428616)) |
| Jun to Sep 2028 | [Carboplatin topline data readout](https://sec-api.dev/pdufa/carboplatin) | EXEL | Squamous Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT07845786 (Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07845786)) |
| June 2028 | [Carboplatin primary completion](https://sec-api.dev/pdufa/carboplatin) | EXEL | Squamous Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT07845786 (Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07845786)) |
| August 2028 | [Zanzalintinib primary completion](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06082167)) |
| Aug to Nov 2028 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06082167)) |
| Jun to Sep 2029 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) | scheduled | "NCT06943755 (Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06943755)) |
| June 2029 | [Zanzalintinib primary completion](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) | scheduled | "NCT06943755 (Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06943755)) |
| Apr to Jul 2030 | [Zanzalintinib topline data readout](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Colorectal Cancer | scheduled | "NCT07750158 (Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-05 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07750158)) |
| April 2030 | [Zanzalintinib primary completion](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | Colorectal Cancer | scheduled | "NCT07750158 (Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-05 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07750158)) |
| May to Aug 2030 | [CABOMETYX® (cabozantinib) topline data readout](https://sec-api.dev/pdufa/cabozantinib) | EXEL | Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET) | scheduled | "NCT07620574 (Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2030-05-31 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07620574)) |
| May 2030 | [CABOMETYX® (cabozantinib) primary completion](https://sec-api.dev/pdufa/cabozantinib) | EXEL | Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET) | scheduled | "NCT07620574 (Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2030-05-31 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07620574)) |

## Drugs

- [CABOMETYX® (cabozantinib)](https://sec-api.dev/pdufa/cabozantinib): previously treated advanced net, measurable, extra-pelvic metastatic castration-resistant prostate cancer, with previously treated advanced net, measurable, extra-pelvic mcrpc, Cancer
- [Cabometyx (cabozantinib s-malate)](https://sec-api.dev/pdufa/cabozantinib-s-malate): 
- [Carboplatin](https://sec-api.dev/pdufa/carboplatin): Squamous Non-Small Cell Lung Cancer (NSCLC), Epithelial Ovarian Cancer
- [Stivarga® (regorafenib)](https://sec-api.dev/pdufa/regorafenib): 
- [XB371](https://sec-api.dev/pdufa/xb371): 
- [XB628](https://sec-api.dev/pdufa/xb628): 
- [XL092](https://sec-api.dev/pdufa/xl092): Colorectal Cancer, Non-Clear Cell Renal Cell Carcinoma
- [Zanzalintinib](https://sec-api.dev/pdufa/zanzalintinib): recurrent grade i/ii/iii meningioma with relapse or progression, previously treated metastatic colorectal cancer, with previously treated metastatic crc, resected stage ii/iii crc, with metastatic crc, metastatic crc, when used in combination with atezolizumab, Meningioma, Colorectal Cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/exel/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EXEL catalysts: EXELIXIS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/exel/catalysts

```bibtex
@misc{secapidev_companies_exel_catalysts_20261116,
  title        = {EXEL catalysts: EXELIXIS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/exel/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_exel_catalysts_20261116","title":"EXEL catalysts: EXELIXIS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/exel/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
